New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLivagen vs LL-37

Livagen vs LL-37

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Livagen
Immune SupportRecovery & Repair
LL-37
Summary
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
Half-Life
Short (minutes); gene-regulatory effects are sustained
Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
Admin Route
SubQ, Oral
SubQ, Topical, Intranasal
Research
Typical Dose
10 mg per day
100–300 mcg
Frequency
Daily for 10–30 days
2–3x per week
Key Benefits
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
  • Broad-spectrum antimicrobial (bacteria, fungi, viruses)
  • Promotes wound healing and angiogenesis
  • Immune system modulation — enhances innate immunity
  • Reduces LPS-mediated endotoxemia
  • Anti-biofilm activity against resistant organisms
  • Promotes tissue regeneration and keratinocyte migration
  • May protect against sepsis
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
  • Injection site redness and irritation
  • Mild inflammatory response at injection site
  • Potential pro-inflammatory at high doses
  • Rare: fever or flu-like symptoms at initiation
Stacks With